DK1248606T3 - Anvendelse af fumarsyrederivater til behandling af mitokondrie-relaterede sygdomme - Google Patents

Anvendelse af fumarsyrederivater til behandling af mitokondrie-relaterede sygdomme

Info

Publication number
DK1248606T3
DK1248606T3 DK00991160T DK00991160T DK1248606T3 DK 1248606 T3 DK1248606 T3 DK 1248606T3 DK 00991160 T DK00991160 T DK 00991160T DK 00991160 T DK00991160 T DK 00991160T DK 1248606 T3 DK1248606 T3 DK 1248606T3
Authority
DK
Denmark
Prior art keywords
fumaric acid
mitochondrial
treatment
acid derivatives
sdh
Prior art date
Application number
DK00991160T
Other languages
English (en)
Inventor
Rajendra Kumar Joshi
Hans-Peter Strebel
Original Assignee
Fumapharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fumapharm Ag filed Critical Fumapharm Ag
Application granted granted Critical
Publication of DK1248606T3 publication Critical patent/DK1248606T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
DK00991160T 2000-01-10 2000-12-11 Anvendelse af fumarsyrederivater til behandling af mitokondrie-relaterede sygdomme DK1248606T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10000577A DE10000577A1 (de) 2000-01-10 2000-01-10 Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten

Publications (1)

Publication Number Publication Date
DK1248606T3 true DK1248606T3 (da) 2006-08-21

Family

ID=7627026

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00991160T DK1248606T3 (da) 2000-01-10 2000-12-11 Anvendelse af fumarsyrederivater til behandling af mitokondrie-relaterede sygdomme

Country Status (28)

Country Link
US (1) US6858750B2 (da)
EP (1) EP1248606B1 (da)
JP (1) JP2003529556A (da)
CN (1) CN1433303A (da)
AT (1) ATE329590T1 (da)
AU (1) AU772409B2 (da)
BG (1) BG65468B1 (da)
BR (1) BR0016935A (da)
CA (1) CA2390886C (da)
CY (1) CY1105462T1 (da)
CZ (1) CZ303680B6 (da)
DE (2) DE10000577A1 (da)
DK (1) DK1248606T3 (da)
EE (1) EE05051B1 (da)
ES (1) ES2265367T3 (da)
HU (1) HU229138B1 (da)
IL (2) IL150516A0 (da)
MX (1) MXPA02006695A (da)
NO (1) NO326875B1 (da)
NZ (1) NZ518781A (da)
PL (1) PL223342B1 (da)
PT (1) PT1248606E (da)
RS (1) RS50185B (da)
RU (1) RU2218918C1 (da)
SI (1) SI1248606T1 (da)
SK (1) SK286719B6 (da)
WO (1) WO2001051047A1 (da)
ZA (1) ZA200205481B (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US7157423B2 (en) * 2001-01-12 2007-01-02 Fumapharm Ag Fumaric acid amides
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
DE10217314A1 (de) * 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
US7224426B2 (en) * 2002-07-31 2007-05-29 Dai Nippon Printing Co., Ltd. Optical element
ATE380027T1 (de) 2003-09-09 2007-12-15 Fumapharm Ag Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma
DE14172390T1 (de) * 2004-10-08 2014-12-31 Forward Pharma A/S Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester
EP1915387B1 (en) * 2005-07-07 2010-01-20 Aditech Pharma AG Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use
EP1915334A2 (en) * 2005-07-07 2008-04-30 Aditech Pharma AB Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
JP5213137B2 (ja) * 2006-12-06 2013-06-19 コーネル リサーチ ファウンデーション， インコーポレイテッド 中程度の持続時間の神経筋遮断剤およびそのアンタゴニスト
EP3135282A1 (en) * 2007-02-08 2017-03-01 Biogen MA Inc. Neuroprotection in demyelinating diseases
EP2680006A1 (en) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Treatment for Amyotrophic Lateral Sclerosis
US8148414B2 (en) 2008-08-19 2012-04-03 Xenoport, Inc. Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
US20120034274A1 (en) * 2009-01-09 2012-02-09 Forward Pharma A/S Pharmaceutical composition comprising one or more fumaric acid esters
US8906420B2 (en) * 2009-01-09 2014-12-09 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
US8592451B2 (en) 2009-03-17 2013-11-26 Cornell University Reversible nondepolarizing neuromuscular blockade agents and methods for their use
US9220700B2 (en) 2009-08-19 2015-12-29 Cornell University Cysteine for physiological injection
CA2865316A1 (en) * 2011-04-28 2012-11-01 Gino Cortopassi Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
NZ618178A (en) 2011-06-08 2016-03-31 Biogen Ma Inc Process for preparing high purity and crystalline dimethyl fumarate
EP2782561A1 (en) 2011-11-24 2014-10-01 Synthon BV Controlled release particles comprising dimethyl fumarate
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
NZ627980A (en) * 2012-02-07 2016-12-23 Biogen Ma Inc Pharmaceutical compositions containing dimethyl fumarate
TWI486339B (zh) 2012-02-07 2015-06-01 Xenoport Inc □啉烷基反丁烯二酸化合物、醫藥組成物以及使用之方法
EP2887934A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
WO2014031897A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral dosage forms having a high loading of (n,n- diethylcarbamoyl)methyl methyl|(2e)but-2-ene-1,4-dioate
TW201436790A (zh) 2012-12-21 2014-10-01 Biogen Idec Inc 經氘取代之反丁烯二酸酯衍生物類
NZ631337A (en) 2013-03-14 2017-01-27 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various diseases
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
SI3253377T1 (sl) 2015-02-08 2021-08-31 Alkermes Pharma Ireland Limited Monometilfumaratni sestavki predzdravil
DK3273951T3 (da) 2015-03-27 2020-11-02 Symbionyx Pharmaceuticals Inc Sammensætninger og fremgangsmåder til behandling af psoriasis
AU2016273068A1 (en) 2015-06-01 2017-12-21 Sun Pharmaceutical Industries Ltd. Pharmaceutical compositions of dimethyl fumarate
WO2017060420A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected fumaric acid-based metabolites for the treatment of autoimmune diseases
IT201700087376A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201700087359A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
RU2674286C1 (ru) * 2018-03-20 2018-12-07 Исмагилов Искандар Халиуллович Средство для лечения заболевания, обусловленного нарушением окислительного стресса
RU2742745C1 (ru) * 2019-09-24 2021-02-10 Акционерное общество "Исследовательский Институт Химического Разнообразия" Лекарственная форма в виде капсулы, содержащая таблетки с диметилфурмаратом

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) * 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) * 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
CH664150A5 (de) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
JPS61194020A (ja) * 1985-02-22 1986-08-28 Dai Ichi Seiyaku Co Ltd 網膜症治療剤
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
IT1251166B (it) * 1991-08-09 1995-05-04 Chiesi Farma Spa Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono
WO1995025102A1 (en) * 1994-03-16 1995-09-21 Novo Nordisk A/S Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
ATE555780T1 (de) * 1997-10-24 2012-05-15 John P Blass Nahrungsergänzungsmittel für metabolische hirnleistungsstörungen
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
AU2001271824A1 (en) * 2000-07-05 2002-01-14 Johns Hopkins School Of Medicine Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes

Also Published As

Publication number Publication date
CZ303680B6 (cs) 2013-02-27
RS50185B (sr) 2009-05-06
ES2265367T3 (es) 2007-02-16
BG106685A (en) 2003-01-31
SK6522002A3 (en) 2002-11-06
CZ20021522A3 (cs) 2002-10-16
EP1248606B1 (de) 2006-06-14
SK286719B6 (sk) 2009-04-06
DE10000577A1 (de) 2001-07-26
MXPA02006695A (es) 2002-10-23
CN1433303A (zh) 2003-07-30
EE200200333A (et) 2003-08-15
PL223342B1 (pl) 2016-10-31
YU51402A (sh) 2006-01-16
EP1248606A1 (de) 2002-10-16
WO2001051047A8 (de) 2001-08-16
NZ518781A (en) 2004-04-30
AU772409B2 (en) 2004-04-29
JP2003529556A (ja) 2003-10-07
WO2001051047A1 (de) 2001-07-19
NO326875B1 (no) 2009-03-09
CA2390886A1 (en) 2001-07-19
US20030013761A1 (en) 2003-01-16
ATE329590T1 (de) 2006-07-15
PL356714A1 (en) 2004-06-28
DE50013000D1 (de) 2006-07-27
HUP0204182A2 (hu) 2003-04-28
AU3156601A (en) 2001-07-24
PT1248606E (pt) 2006-08-31
HU229138B1 (en) 2013-08-28
HUP0204182A3 (en) 2003-05-28
IL150516A (en) 2009-02-11
BR0016935A (pt) 2003-04-01
SI1248606T1 (sl) 2006-10-31
CA2390886C (en) 2008-08-19
CY1105462T1 (el) 2010-04-28
NO20022175D0 (no) 2002-05-07
IL150516A0 (en) 2003-02-12
EE05051B1 (et) 2008-08-15
NO20022175L (no) 2002-05-07
ZA200205481B (en) 2004-01-28
RU2218918C1 (ru) 2003-12-20
BG65468B1 (bg) 2008-09-30
US6858750B2 (en) 2005-02-22

Similar Documents

Publication Publication Date Title
DK1248606T3 (da) Anvendelse af fumarsyrederivater til behandling af mitokondrie-relaterede sygdomme
UA74346C2 (uk) Похідні амінодикарбонових кислот, їх застосування та лікарський засіб
BR0108452A (pt) Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva
NZ514234A (en) N-cyanomethylamides as protease inhibitors
TR200200648T2 (tr) Farmasötik özelliklere sahip yeni dikarboksilik asit türevleri.
TR200001189T2 (tr) Dipeptid nitriller.
TR199801642T2 (xx) Tedavide faydal� olan karbamik asitlerin azabisiklik esterleri.
ES2103587T3 (es) Composiciones terapeuticas ingeribles, estables y absorbibles de nadh y de nadph.
CY1107600T1 (el) Κρεμα για τη θepαπεια δερματος τραυματισμενου απο τον ηλιο
TR200200263T2 (tr) Yeni seçiçi retinoid agonistleri
DE50108339D1 (de) Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln zur behandlung von erkrankungen rheumatischer natur
RS50129B (sr) Optički aktivan derivat piridil-4h-1,2,4-oksadiazina i njegova upotreba u proizvodnji lekova za tretiranje vaskularnih bolesti
DE60122917D1 (de) Fermentative herstellung von d-p-hydroxyphenylglycin und d-phenylglycin
CY1106168T1 (el) Συνθεση για την προληψη και/ή θepαπεια αγγειακων ασθενειων που συνισταται απο προπιονυλ l-καρνιτινη και συνενζυμο q10
SE0000055D0 (sv) Novel process
NO20043286L (no) Piperidinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
ATE330597T1 (de) Verwendung von fibrate zur herstellung eines arzneimittel zur behandlung von kongestiven herzversagens
UY26930A1 (es) Amidas de ácido fenilciclohexanocarboxílico sustituido y su uso
UY27475A1 (es) Amidas de ácido piperazinciclohexanocarboxílico sustituidas y su utilización
NO20044555L (no) Kombinasjonsprodukt omfattende en antikoagulant og anti-arrytmiske oksabispidener
ATE129244T1 (de) 4-((thiophen-2-carbonyl)oxy&gt;pyrrolidin-2- carbonsäure, deren herstellung und deren verwendung als entzündungshemmendes und wundheilendes mittel.
YU89903A (sh) Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa i -gama aktivatori u lečenju dijabetesa
UA41037A (uk) Препарат для лікування захворювань порожнини роту